Ophthalmology · 1997
Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure.
Клиническое исследованиеСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rulo A H, Greve E L, Hoyng P F
Аннотация
OBJECTIVE: To investigate the additive ocular hypotensive effect of latanoprost on the intraocular pressure (IOP) reduction induced by a suboptimal dose of acetazolamide, a carbonic anhydrase inhibitor.
DESIGN: A short-term, randomized, placebo-controlled, double-masked study.
PARTICIPANTS: Twenty-four patients with glaucoma with elevated IOPs.
INTERVENTION: Acetazolamide 250 mg twice daily from day 1 to day 18. Topical 50 micrograms/ml latanoprost or placebo eye drops bilaterally instilled once daily from day 4 to day 18.
MEAN OUTCOME MEASURES: IOP, conjunctival hyperemia.
RESULTS: The mean IOP of 19.5 mmHg during acetazolamide treatment was further reduced to 16.8 mmHg after topical administration of latanoprost, i.e., a decrease of 2.9 +/- 2.8 mmHg (15%, P < 0.001). Administration of placebo to patients on acetazolamide resulted in an upward drift of 1.3 mmHg (6%, P = 0.03). A modest but statistically significant increase in conjunctival hyperemia was found in the latanoprost-treated group, but did not affect the masking.
CONCLUSIONS: This short-term study indicates that the combination of topically applied latanoprost and a suboptimal dose of systemic carbonic anhydrase inhibitor is useful in the management of glaucoma.
DESIGN: A short-term, randomized, placebo-controlled, double-masked study.
PARTICIPANTS: Twenty-four patients with glaucoma with elevated IOPs.
INTERVENTION: Acetazolamide 250 mg twice daily from day 1 to day 18. Topical 50 micrograms/ml latanoprost or placebo eye drops bilaterally instilled once daily from day 4 to day 18.
MEAN OUTCOME MEASURES: IOP, conjunctival hyperemia.
RESULTS: The mean IOP of 19.5 mmHg during acetazolamide treatment was further reduced to 16.8 mmHg after topical administration of latanoprost, i.e., a decrease of 2.9 +/- 2.8 mmHg (15%, P < 0.001). Administration of placebo to patients on acetazolamide resulted in an upward drift of 1.3 mmHg (6%, P = 0.03). A modest but statistically significant increase in conjunctival hyperemia was found in the latanoprost-treated group, but did not affect the masking.
CONCLUSIONS: This short-term study indicates that the combination of topically applied latanoprost and a suboptimal dose of systemic carbonic anhydrase inhibitor is useful in the management of glaucoma.
Предметные рубрики MeSH
AcetazolamideAdministration, OralAdministration, TopicalAgedCarbonic Anhydrase InhibitorsConjunctivaConjunctival DiseasesDouble-Blind MethodDrug SynergismDrug Therapy, CombinationFemaleGlaucoma, Open-AngleHumansHyperemiaIntraocular PressureLatanoprostMaleMiddle AgedOcular HypertensionOphthalmic SolutionsProstaglandins F, Synthetic